Open AccessRexinoid Bexarotene Modulates Triglyceride but not Cholesterol Metabolism via Gene-Specific Permissivity of the RXR/LXR Heterodimer in the Liver
Author(s) -
Fanny Lalloyer,
Thomas Åskov Pedersen,
Barbara Gross,
Sophie Lestavel,
Saı̈d Yous,
Emmanuelle Vallez,
Jan-Ακε Gustafsson,
Susanne Mandrup,
Catherine Fiévet,
Bart Staels,
Anne Tailleux
Publication year - 2009
Publication title -
arteriosclerosis thrombosis and vascular biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.007
H-Index - 270
eISSN - 1524-4636
pISSN - 1079-5642
DOI - 10.1161/atvbaha.109.189506
Subject(s) - bexarotene , liver x receptor , retinoid x receptor , lipogenesis , chromatin immunoprecipitation , hypertriglyceridemia , biology , cholesterol , nuclear receptor , chemistry , endocrinology , medicine , triglyceride , lipid metabolism , biochemistry , transcription factor , gene expression , promoter , gene
Bexarotene (Targretin) is a clinically used antitumoral agent which exerts its action through binding to and activation of the retinoid-X-receptor (RXR). The most frequent side-effect of bexarotene administration is an increase in plasma triglycerides, an independent risk factor of cardiovascular disease. The molecular mechanism behind this hypertriglyceridemia remains poorly understood.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom